Glenmark Pharmaceuticals has announced that it plans to spin off a US-based company for development of innovative drugs, including GRC 39815, a retinoid-related orphan receptor gamma t (RORγt) inhibitor in pre-clinical development as a potential inhaled treatment for COPD. The new US-based company is expected to employ over 400 people, and all employees, assets, … [Read more...] about Glenmark inhaled RORγt inhibitor to be developed by US spin-off
Business
VistaGen gets notice of allowance for patent covering PH10 nasal spray for the treatment of depression
The US Patent and Trademark Office (USPTO) has provided VistaGen a notice of allowance regarding a patent covering the use of its PH10 nasal spray for the treatment of depression, the company said. VistaGen announced that it had licensed PH10, a neurosteroid nasal spray, from Pherin Pharmaceuticals in October 2018. PH10 is currently in Phase 2 development for the … [Read more...] about VistaGen gets notice of allowance for patent covering PH10 nasal spray for the treatment of depression
GSK, Mylan launch generic versions of Advair Diskus in US
Both GSK and Mylan have announced the availability of generic versions of GSK's Advair Diskus fluticasone propionate/salmeterol DPI in the US. GSK made a statement regarding its authorized generic on February 8, 2019, and Mylan has responded by announcing the US launch of the Wixela Inhub fluticasone propionate/salmeterol DPI, which was recently approved by … [Read more...] about GSK, Mylan launch generic versions of Advair Diskus in US
Pulmatrix gets five new patents for DPI formulations
Pulmatrix announced that it has received five new patents covering PUR1800 and PUR5700, which are inhaled narrow spectrum kinase inhibitors that Pulmatrix licensed from Janssen subsidiary RespiVert in June 2017. The new patents include two US patents (Nos. 9,884,845 B2 and 10,045,980 B2) and two European patents (Nos. 3105222 B1 and 3105223 B1) covering RV-7031, … [Read more...] about Pulmatrix gets five new patents for DPI formulations
Orion’s Easyhaler products to connect to Propeller Health inhaler montitoring platform
Orion and Propeller Health have announced that they will co-develop a custom sensor for Orion's Easyhaler devices that will allow the inhalers to connect to Propeller's digital inhaler monitoring platform. According to the companies, "Development of the sensor will begin in 2019, with clinical trials, possible real world evidence projects and a broader commercial … [Read more...] about Orion’s Easyhaler products to connect to Propeller Health inhaler montitoring platform
Avadel Pharmaceuticals drops Noctiva nasal spray
Avadel Specialty Pharmaceuticals, which marketed Noctiva desmopressin nasal spray in the US, has filed for Chapter 11 bankruptcy, parent company Avadel Pharmaceuticals announced. Less than a year after launching Noctiva in the US, Avadel said that it will no longer market the product. Noctiva was approved by the FDA in March 2017 for the treatment of nocturnal … [Read more...] about Avadel Pharmaceuticals drops Noctiva nasal spray
Grandpharma acquires Chinese rights to Ryaltris nasal spray
Glenmark Pharmaceuticals announced that it has agreed to a licensing deal giving Grandpharma exclusive rights to commercialize Ryaltris olopatadine hydrochloride/mometasone furoate nasal spray in China. The company recently announced that Yuhan had acquired South Korean rights to Ryaltris in South Korea. In July 2018, Glenmark said that it had reached an agreement … [Read more...] about Grandpharma acquires Chinese rights to Ryaltris nasal spray
Senzer inhaler wins second design award
Senzer's Systemic inhaled Delivery Device (SiDD) has won an iF Design Award in the Medicine/Health product category, the company said. The inhaler also recently won a 2018 Good Design award in the medical category. The company is developing several cannabinoid products, including dronabinol and cannabidiol inhalers, based on the breath activated SiDD platform, … [Read more...] about Senzer inhaler wins second design award
AIT Therapeutics gets milestone payment from Circassia on completion of pre-submission meeting for AirNOvent
AIT Therapeutics said that it has received a $3.15 million milestone payment from Circassia Pharmaceuticals after successful completion of a pre-submission meeting with the FDA for AirNOvent nitric oxide delivery system. Circassia recently announced that it had acquired US and Chinese rights to the product. In a separate announcement, Circassia said that it will … [Read more...] about AIT Therapeutics gets milestone payment from Circassia on completion of pre-submission meeting for AirNOvent
Mylan announces plans for launch of Wixela Inhub, its generic version of Advair Diskus
One day after the FDA announced that it has approved Mylan's ANDA for Wixela Inhub, a generic version of Advair Diskus fluticasone propionate/salmeterol DPI, Mylan has announced that it will launch the product by the end of February. The FDA approved Wixela Inhub in three strengths for the treatment of COPD and for the treatment of asthma in patients aged 4 years and … [Read more...] about Mylan announces plans for launch of Wixela Inhub, its generic version of Advair Diskus